Bin Xiao

Dr. Bin Xiao

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BXBin Xiao
Bin Xiao
JGJian-Yuan Goh
Jian-Yuan Goh
LXLin Xiao
Lin Xiao
HXHongxu Xian
Hongxu Xian
KLKah Leong Lim
Kah Leong Lim
YLYih-Cherng Liou
Yih-Cherng Liou
Defective mitophagy linked to dysfunction in the proteins Parkin and PTEN-induced putative kinase 1 (PINK1) is implicated in the pathogenesis of Parkinson's disease. Although the mechanism by which Parkin mediates mitophagy in a PINK1-dependent manner is becoming clearer, the triggers for this mitophagy pathway remain elusive. Reactive oxygen species (ROS) have been suggested as such triggers, but this proposal remains controversial because ROS scavengers fail to retard mitophagy. Here we demonstrate that the role of ROS in mitophagy has been underappreciated as a result of the inefficiency of ROS scavengers to control ROS bursts after high-dose treatment with carbonyl cyanide m-chlorophenylhydrazone. Supporting this, combinatorial treatment with N-acetyl-l-cysteine and catalase substantially inhibited the ROS upsurge and PINK1-dependent Parkin translocation to mitochondria in response to carbonyl cyanide m-chlorophenylhydrazone treatment. In addition to the chemical mitophagy inducer, overexpression of voltage-dependent anion channel 1 (VDAC1) induced Parkin translocation to mitochondria, presumably by stimulating ROS generation. Similarly, combined N-acetyl-l-cysteine and catalase treatment also suppressed VDAC1-induced redistribution of Parkin. Alongside these observations, we also found that the elevated protein level of PINK1 was not necessary for Parkin translocation to mitochondria. Thus, our data suggest that ROS may act as a trigger for the induction of Parkin/PINK1-dependent mitophagy. In addition, our study casts doubt on the importance of protein quantity of PINK1 in the recruitment of Parkin to mitochondria.

30 March 2016 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
BXBin Xiao
Bin Xiao
XDXiao Deng
Xiao Deng
WZWei Zhou
Wei Zhou
Eng King TanEng King Tan
Eng King Tan
Flow Cytometry-Based Assessment of Mitophagy Using MitoTracker

12 October 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
BXBin Xiao
Bin Xiao
XDXiao Deng
Xiao Deng
GLGrace G Y Lim
Grace G Y Lim
SXShaoping Xie
Shaoping Xie
ZZZhi Dong Zhou
Zhi Dong Zhou
Eng King TanEng King Tan
Eng King Tan
Reactive oxygen species (ROS) and mitophagy are profoundly implicated in the pathogenesis of neurodegenerative diseases, such as Parkinson’s disease (PD). Several studies have suggested that ROS are not involved in mitochondrial translocation of Parkin which primes mitochondria for autophagic elimination. However, whether ROS play a role in the execution of mitophagy is unknown. In the present study, we show that carbonyl cyanidem-chlorophenylhydrazone (CCCP) treatment induced both mitochondrial depolarization and generation of ROS that were needed for the mitophagy process. Cells failed to proceed to complete mitophagy if CCCP treatment was discontinued even after recruitment of Parkin and autophagy machinery to mitochondria. Notably, treatment of pro-oxidant was able to replace CCCP treatment to take mitophagy forward, while it alone was insufficient to induce translocation of Parkin to mitochondria or autophagic clearance of mitochondria. In addition, an SOD mimetic that attenuated the superoxide level suppressed mitophagy, while an SOD inhibitor accumulated cellular superoxide and promoted mitophagy. Furthermore, blockage of the p38 signaling pathway inhibited mitophagy induced by ROS, suggesting that it may contribute to the activation of ROS-mediated mitophagy. Together, our study sheds light on the link between ROS and mitophagy at a molecular level, and suggests the therapeutic potential of regulating mitophagy through the superoxide–p38–mitophagy axis.

18 October 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
BXBin Xiao
Bin Xiao
JKJoshua Kuruvilla
Joshua Kuruvilla
Eng King TanEng King Tan
Eng King Tan
Mitophagy impairment and oxidative stress are cardinal pathological hallmarks in Parkinson’s disease (PD), a common age-related neurodegenerative condition. The specific interactions between mitophagy and reactive oxygen species (ROS) have attracted considerable attention even though their exact interplay in PD has not been fully elucidated. We highlight the interactions between ROS and mitophagy, with a focus on the signalling pathways downstream to ROS that triggers mitophagy and draw attention to potential therapeutic compounds that target these pathways in both experimental and clinical models. Identifying a combination of ROS inhibitors and mitophagy activators to provide a physiologic balance in this complex signalling pathways may lead to a more optimal outcome. Deciphering the exact temporal relationship between mitophagy and oxidative stress and their triggers early in the course of neurodegeneration can unravel mechanistic clues that potentially lead to the development of compounds for clinical drug trials focusing on prodromic PD or at-risk individuals.

10 September 2008 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JGJi‐Feng Guo
Ji‐Feng Guo
BXBin Xiao
Bin Xiao
BLBing Liao
Bing Liao
XZXue‐Wei Zhang
Xue‐Wei Zhang
LNLi‐Luo Nie
Li‐Luo Nie
BTBei‐Sha Tang
Bei‐Sha Tang

15 October 2009 in Movement Disorders
Verified
Journal Article
Open access
PDF file
JWJun‐Ling Wang
Jun‐Ling Wang
BXBin Xiao
Bin Xiao
XCXiang‐Xiang Cui
Xiang‐Xiang Cui
JGJi‐Feng Guo
Ji‐Feng Guo
LLLi‐Fang Lei
Li‐Fang Lei
BTBei‐Sha Tang
Bei‐Sha Tang
To investigate the prevalence and clinical feature(s) of Parkinson's disease (PD) patients with expanded (ATXN2 and MJD1) genes of spinocerebellar ataxia type 2 and 3 (SCA2 and SCA3/MJD) in a mainland Chinese population, CAG triplet repeat expansions of (SCA2 and SCA3/MJD) genes (ATXN2 and MJD1) were analyzed in a cohort of 452 PD patients, including 386 sporadic and 66 familial forms. Striatal dopamine transporter was evaluated in two SCA2 and two SCA3/MJD‐positive family members, an idiopathic PD patient and a healthy control using carbon (C11) [11C]‐radiolabeled‐CFT positron emission tomography (PET). We found two patients in one familial PD (FPD) family (1.5%) and two sporadic PD patients (0.5%) with expanded CAG repeats in the ATXN2 locus, four patients in two FPD families (3%) and another three sporadic PD patients (0.8%) in the MJD1 locus. [11C]‐CFT PET in detected members in SCA2 and SCA3/MJD families showed decrements of 11C‐CFT uptake. These findings suggest that a mutation in SCA2 or SCA3/MJD may be one of the genetic causes of PD. © 2009 Movement Disorder Society